Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure (CARNEBI)

This study has been completed.
Information provided by:
Centro Cardiologico Monzino Identifier:
First received: August 16, 2007
Last updated: September 15, 2010
Last verified: September 2010

The investigators test the hypothesis that different beta-blockers had a different influence on chemoreceptor response and lung diffusion capacity.

Both could influence exercise capacity in normoxic as well as hypoxic conditions.

Condition Intervention Phase
Chronic Heart Failure
Drug: carvedilol
Drug: bisoprolol
Drug: Nebivolol
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure: Effects on Exercise Capacity and Hypoxia, Chemoreceptor Response, Pulmonary Function

Resource links provided by NLM:

Further study details as provided by Centro Cardiologico Monzino:

Primary Outcome Measures:
  • exercise capacity [ Time Frame: two months ]

Secondary Outcome Measures:
  • lung diffusion [ Time Frame: two months ]

Enrollment: 60
Study Start Date: July 2007
Study Completion Date: May 2010
Arms Assigned Interventions
Active Comparator: Carvedilol Drug: carvedilol
Active Comparator: Bisoprolol Drug: bisoprolol
Active Comparator: Nebivolol Drug: Nebivolol


Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Chronic heart failure patients in stable clinical condition

Exclusion Criteria:

  • No comorbidity
  • NYHA class IV
  Contacts and Locations
Please refer to this study by its identifier: NCT00517725

Centro Cardiologico Monzino, University of Milan
Milan, Italy, 20138
Sponsors and Collaborators
Centro Cardiologico Monzino
Principal Investigator: Piergiuseppe Agostoni, MD, PhD Centro Cardiologico Monzino
Study Chair: Giancarlo Marenzi, MD Centro Cardiologico Monzino
  More Information

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Piergiuseppe Agostoni, Centro Cardiologico Monzino - Univeristy of Milan Identifier: NCT00517725     History of Changes
Other Study ID Numbers: R76-CCM S78/407
Study First Received: August 16, 2007
Last Updated: September 15, 2010
Health Authority: Italy: Ministry of Health

Keywords provided by Centro Cardiologico Monzino:
lung diffusion
heart failure

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists processed this record on April 22, 2014